Andrea Macko is reporting for Porcupine Soup the GlaxoSmithKline Consumer Healthcare division is expected to soon become an independent company. The newly created Haleon [Hay-lee-on] will be “a world-leader in consumer healthcare,” with a portfolio of global names, including Sensodyne, Voltaren, Panadol and Centrum. Sensodyne is among the products manufactured at the GlaxoSmithKline facility in Oak Hill on State Route 145. Representatives from GSK have yet to comment on how the demerger will impact Oak Hill, but a changeover to Haleon is expected, according to sources. GSK shareholders will likely vote on the demerger in July. Under the corporate restructuring plan, GSK will retain its vaccine and pharmaceutical divisions. In late February, the English company inquired with the Greene County Industrial Development Agency about a new PILOT, or payment-in-lieu-of-taxes agreement. “Their PILOT ended over a year ago,” IDA Executive Director April Ernst told the IDA Board of Directors at its February meeting. “They wanted to ask about extending their PILOT or a new PILOT. I explained that the IDA doesn’t roll back taxes, we don’t harm the jurisdictions. So if they feel that their assessment is high, they should work on an appraisal or work with the town.” GlaxoSmithKline's last PILOT was part of an incentive package negotiated 10 years ago to keep company operations in Oak Hill and retain 260 local jobs. Currently, GSK is taxed at full assessment value on its multiple parcels on State Route 145 and Elliot Place. Read the full story at porcupine soup [dot] com.